222 related articles for article (PubMed ID: 34696251)
1. Blocking HIF to Enhance NK Cells: Hints for New Anti-Tumor Therapeutic Strategies?
Vitale M; Parodi M
Vaccines (Basel); 2021 Oct; 9(10):. PubMed ID: 34696251
[TBL] [Abstract][Full Text] [Related]
2. NK cell-based therapeutics for lung cancer.
Pockley AG; Vaupel P; Multhoff G
Expert Opin Biol Ther; 2020 Jan; 20(1):23-33. PubMed ID: 31714156
[No Abstract] [Full Text] [Related]
3. Gene transfer of antisense hypoxia inducible factor-1 alpha enhances the therapeutic efficacy of cancer immunotherapy.
Sun X; Kanwar JR; Leung E; Lehnert K; Wang D; Krissansen GW
Gene Ther; 2001 Apr; 8(8):638-45. PubMed ID: 11320410
[TBL] [Abstract][Full Text] [Related]
4. The role of HIF-1 in up-regulating MICA expression on human renal proximal tubular epithelial cells during hypoxia/reoxygenation.
Luo L; Lu J; Wei L; Long D; Guo JY; Shan J; Li FS; Lu PY; Li PY; Feng L
BMC Cell Biol; 2010 Nov; 11():91. PubMed ID: 21092233
[TBL] [Abstract][Full Text] [Related]
5. HIF-1α induces immune escape of prostate cancer by regulating NCR1/NKp46 signaling through miR-224.
Chen CH; Li SX; Xiang LX; Mu HQ; Wang SB; Yu KY
Biochem Biophys Res Commun; 2018 Sep; 503(1):228-234. PubMed ID: 29885835
[TBL] [Abstract][Full Text] [Related]
6. Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells.
Kim N; Kim HS
Front Immunol; 2018; 9():2041. PubMed ID: 30250471
[TBL] [Abstract][Full Text] [Related]
7. Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor Activity.
Dahlberg CI; Sarhan D; Chrobok M; Duru AD; Alici E
Front Immunol; 2015; 6():605. PubMed ID: 26648934
[TBL] [Abstract][Full Text] [Related]
8. Single-Cell RNA Sequencing of Tumor-Infiltrating NK Cells Reveals that Inhibition of Transcription Factor HIF-1α Unleashes NK Cell Activity.
Ni J; Wang X; Stojanovic A; Zhang Q; Wincher M; Bühler L; Arnold A; Correia MP; Winkler M; Koch PS; Sexl V; Höfer T; Cerwenka A
Immunity; 2020 Jun; 52(6):1075-1087.e8. PubMed ID: 32445619
[TBL] [Abstract][Full Text] [Related]
9. Design and Implementation of NK Cell-Based Immunotherapy to Overcome the Solid Tumor Microenvironment.
Navin I; Lam MT; Parihar R
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33371456
[TBL] [Abstract][Full Text] [Related]
10. Harnessing NK cells for cancer immunotherapy: immune checkpoint receptors and chimeric antigen receptors.
Kim N; Lee DH; Choi WS; Yi E; Kim H; Kim JM; Jin HS; Kim HS
BMB Rep; 2021 Jan; 54(1):44-58. PubMed ID: 33298244
[TBL] [Abstract][Full Text] [Related]
11. Unleashing Natural Killer Cells in the Tumor Microenvironment-The Next Generation of Immunotherapy?
Ben-Shmuel A; Biber G; Barda-Saad M
Front Immunol; 2020; 11():275. PubMed ID: 32153582
[TBL] [Abstract][Full Text] [Related]
12. Strategies to Augment Natural Killer (NK) Cell Activity against Solid Tumors.
Chen Z; Yang Y; Liu LL; Lundqvist A
Cancers (Basel); 2019 Jul; 11(7):. PubMed ID: 31340613
[TBL] [Abstract][Full Text] [Related]
13. Patient's Natural Killer Cells in the Era of Targeted Therapies: Role for Tumor Killers.
Messaoudene M; Frazao A; Gavlovsky PJ; Toubert A; Dulphy N; Caignard A
Front Immunol; 2017; 8():683. PubMed ID: 28659921
[TBL] [Abstract][Full Text] [Related]
14. Combination immune therapies to enhance anti-tumor responses by NK cells.
Mentlik James A; Cohen AD; Campbell KS
Front Immunol; 2013 Dec; 4():481. PubMed ID: 24391651
[TBL] [Abstract][Full Text] [Related]
15. Viral and Nonviral Engineering of Natural Killer Cells as Emerging Adoptive Cancer Immunotherapies.
Matosevic S
J Immunol Res; 2018; 2018():4054815. PubMed ID: 30306093
[TBL] [Abstract][Full Text] [Related]
16. Immune Circuits to Shape Natural Killer Cells in Cancer.
Mattiola I
Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34203391
[TBL] [Abstract][Full Text] [Related]
17. Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy.
Davis ZB; Vallera DA; Miller JS; Felices M
Semin Immunol; 2017 Jun; 31():64-75. PubMed ID: 28882429
[TBL] [Abstract][Full Text] [Related]
18. Natural killer group 2D receptor and its ligands in cancer immune escape.
Duan S; Guo W; Xu Z; He Y; Liang C; Mo Y; Wang Y; Xiong F; Guo C; Li Y; Li X; Li G; Zeng Z; Xiong W; Wang F
Mol Cancer; 2019 Feb; 18(1):29. PubMed ID: 30813924
[TBL] [Abstract][Full Text] [Related]
19. NK Cell Adoptive Immunotherapy of Cancer: Evaluating Recognition Strategies and Overcoming Limitations.
Sanchez CE; Dowlati EP; Geiger AE; Chaudhry K; Tovar MA; Bollard CM; Cruz CRY
Transplant Cell Ther; 2021 Jan; 27(1):21-35. PubMed ID: 33007496
[TBL] [Abstract][Full Text] [Related]
20. Overcoming Resistance to Natural Killer Cell Based Immunotherapies for Solid Tumors.
Nayyar G; Chu Y; Cairo MS
Front Oncol; 2019; 9():51. PubMed ID: 30805309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
